RPL29P4: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: RPL29P4

NCBI ID: G387101

RPL29P4

Other Name(s): bA632C17A.1 | RPL29_6_745 | Ribosomal protein L29 pseudogene 4 | RPL29P3 | ribosomal protein L29 pseudogene 4

RPL29P4: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Introduction

RPL29P4 (bA632C17A.1), a gene encoding a protein known as RNA-protein-protein (RNA-propro) complex subunit 29 (RPL29), has emerged as a promising drug target and biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease , Parkinson's disease, and other neuroinflammatory conditions. Its unique structure, function, and regulation by microRNA (miRNA) pathways make it an attractive target for the development of new therapeutic approaches.

Structure and Function

RPL29P4 is a 29kDa protein that consists of three subunits: RPL29, RPL28, and RPL27. RPL29 is the catalytic subunit, responsible for the formation of the RNA-protein-protein complex, while RPL28 and RPL27 serve as subunit 2 and subunit 3, respectively. The RNA-protein-protein complex plays a central role in the regulation of gene expression and protein stability, ensuring the accuracy and reliability of cellular information.

The RPL29P4 gene is located on chromosome 6 (3), and its expression is highly regulated by miRNA pathways. miRNA is a class of non-coding RNA molecules, consisting of a single strand of approximately 20-22nt, which binds to the 3' end of target mRNA. Regulate its stability, expression level and degradation. miRNA has important biological functions in cells, such as regulating gene expression, controlling cell cycle, participating in apoptosis, etc..

RPL29P4 is a miRNA target, and its expression is known to be regulated by several miRNAs, including miR-202, miR-18a, miR-30, and miR-198. The binding of RPL29P4 will reduce the stability of RPL29P4, making it more susceptible to degradation, thus increasing its possibility as a drug target.

In addition to its role in miRNA regulation, RPL29P4 has also been shown to play a crucial role in the regulation of protein stability and localization. Its association with protein-protein interaction (PPI) networks and its role in modulating the activity of protein kinases, such as casein kinase 2 (CK2), further supports its potential as a drug target.

Drug Interaction with RPL29P4

Several experimental studies have investigated the potential drug targets and biomarkers associated with RPL29P4. One of the most promising approaches is the use of small molecules (8) or antibodies (9) to modulate the activity of RPL29P4 and affect its function as a drug target.

One of the most well-studied targets is the serine/threonine protein kinase casein kinase 2 (CK2). CK2 is a key regulator of the PI3K/AKT signaling pathway, which is involved in the regulation of cell survival and proliferation. RPL29P4 has been shown to interact with CK2 and regulate its activity, which may contribute to its potential as a drug target.

Anti-inflammatory agents, such as corticosteroids, have also been shown to interact with RPL29P4 and modulate its function as a drug target. The use of these agents may provide a new approach to treat neuroinflammatory diseases.

Conclusion

In conclusion, RPL29P4 is a promising drug target and biomarker for the treatment of

Protein Name: Ribosomal Protein L29 Pseudogene 4

The "RPL29P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL29P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets